Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $11.4 million.
- Rocket Pharmaceuticals' Accumulated Expenses rose 1078.91% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 1078.91%. This contributed to the annual value of $11.9 million for FY2024, which is 2028.2% up from last year.
- Per Rocket Pharmaceuticals' latest filing, its Accumulated Expenses stood at $11.4 million for Q3 2025, which was up 1078.91% from $8.0 million recorded in Q2 2025.
- Over the past 5 years, Rocket Pharmaceuticals' Accumulated Expenses peaked at $11.9 million during Q4 2024, and registered a low of $1.6 million during Q1 2022.
- In the last 5 years, Rocket Pharmaceuticals' Accumulated Expenses had a median value of $6.2 million in 2021 and averaged $6.6 million.
- In the last 5 years, Rocket Pharmaceuticals' Accumulated Expenses plummeted by 7357.36% in 2022 and then soared by 15681.96% in 2023.
- Rocket Pharmaceuticals' Accumulated Expenses (Quarter) stood at $4.5 million in 2021, then skyrocketed by 120.74% to $10.0 million in 2022, then decreased by 0.76% to $9.9 million in 2023, then increased by 20.28% to $11.9 million in 2024, then fell by 4.31% to $11.4 million in 2025.
- Its Accumulated Expenses stands at $11.4 million for Q3 2025, versus $8.0 million for Q2 2025 and $7.1 million for Q1 2025.